The highly anticipated 2024 Hunan Province Enterprise Tax Contribution “Four Major Lists” were officially announced yesterday. Jiudian Pharmaceutical, with its outstanding tax contributions, successfully made it onto all four lists and ranked among the top in several subcategories.

The "Four Major Lists," including the Hunan Province Top 100 Enterprises by Tax Contribution, are authoritative rankings published after a joint review by relevant departments based on documents issued by the Provincial Party Committee Office and the Provincial Government Office. These rankings aim to foster a business environment that promotes legal operation and honest tax payment, raise awareness of key tax-paying enterprises, and contribute to the high-quality development of the province's economy and society. Jiudian Pharmaceutical has now been included in all four lists for two consecutive years.

Specifically, Jiudian Pharmaceutical ranks 73rd on the "2024 Hunan Province Top 100 Enterprises by Tax Contribution" and 2nd in the pharmaceutical manufacturing sector; 17th on the "2024 Hunan Province Top 100 Private Enterprises by Tax Contribution"; 22nd on the "2024 Hunan Province Top 100 High-Tech Enterprises by Tax Contribution"; and an impressive 2nd on the "2024 Hunan Province Top 50 Specialized, Refined, Differentiated, and Innovative (Specialized New) Small and Medium-Sized Enterprises by Tax Contribution."

In 2024, the company achieved a revenue of 2.931 billion yuan, with taxes paid exceeding 300 million yuan. Both revenue and tax contributions showed steady growth, making a positive impact on local economic development and improving people's livelihoods. Notably, the company continues to maintain strong growth momentum in the High-Tech Enterprise Tax Contribution list, reflecting its ongoing commitment to increasing research and development (R&D) investment and driving innovation.

Innovation has always been the core driving force behind the company’s development. While improving operational performance, Jiudian Pharmaceutical continues to increase R&D investment and focus on innovative drug development, laying a solid foundation for sustainable growth. The company has been ranked among China's Top 100 Pharmaceutical R&D Companies for several years, with its ranking steadily rising. It has successfully entered the 2025 China Pharmaceutical R&D Comprehensive Strength List at 55th place, a significant improvement of 40 places from 2021. In the Chemical Pharmaceutical R&D Strength List, the company has steadily risen to 28th place.

Over the past year, Jiudian Pharmaceutical has also received recognition for its smart manufacturing and product quality. Its Ketoprofen Gel Patch and Sirolimus API were selected as key products in Hunan’s biopharmaceutical industry chain. The subsidiary Pudao Pharmaceutical was recognized as a “Hunan Provincial Enterprise Technology Center,” while the Jiudian Hongyang Sixth Workshop was awarded the title of “Hunan Provincial Smart Manufacturing Benchmark Workshop.”

As one of the benchmark enterprises in Hunan’s biopharmaceutical industry, Jiudian Pharmaceutical will continue to follow a high-quality development path. While strengthening its core business, the company will persist in its focus on innovative drug research and development and actively explore new paths in the health industry, contributing even more to the vision of Hunan’s “Three Highs and Four News” (High-tech, High-value, High-efficiency and New Industries, New Business Models, New Technologies, and New Products).